AIGP Health wins HSA approval for AI clinical assistant Anzu
AIGP Health has become the first AI healthcare platform in Singapore to receive Class A approval from the Health Sciences Authority (HSA) for its AI-powered clinical assistant.
This designation enables AIGP Health to distribute its clinical assistant to clinics and telehealth providers throughout Singapore and in regional markets. Developed by a team of practising doctors, the platform employs natural language processing to assist healthcare professionals with real-time clinical note-taking, data summarisation, and consultation prompts. The system is classified as non-autonomous, and all clinical decisions remain under physician supervision, complying with HSA guidelines for low-risk medical software.
Regulatory approval for the platform affirms AIGP Health's stated commitment to building products intended to support, rather than replace, human clinical judgement, aligning with Singapore's regulatory direction for responsible artificial intelligence in medicine.
"Regulatory approval isn't just a milestone for us, it's an affirmation of our belief that technology can support, not substitute, the human touch in healthcare," said Dr Anindita Santosa, Co-founder and CEO of AIGP Health. "This approval allows us to move from pilots to deployment, and bring our platform to more clinics, GPs, and telehealth providers, easing the administrative burden for doctors and improving continuity of care for patients."
The platform, known as Anzu, has already been piloted in Singapore and Australia with general practitioners using the tool to streamline documentation, prompt clinical questions, and identify critical information in patient histories. Expansion into Indonesia and Malaysia is also underway, facilitated through collaboration with Borderless Healthcare Group.
Market expansion
The newly received Class A approval has paved the way for AIGP Health to enter commercial discussions with healthcare service providers, especially telehealth platforms. These provider groups may benefit from the software's features such as automatically pre-filling records, identifying missing information, and improving the quality of consultations in digital settings where clinical pace can be especially high.
AIGP Health has also achieved SOC 2 compliance, demonstrating its alignment with best practices in data privacy and security. This compliance is considered important as the company looks to scale its systems and operations to new healthcare markets. The security framework behind AIGP Health is designed according to established industry standards, with policies and controls tailored to protect sensitive clinical information while permitting ongoing development of AI-powered healthcare tools.
Regulatory approach
Singapore's regulatory landscape for digital health continues to evolve. In March 2025, HSA opened a public consultation regarding new exemptions and risk classifications for AI-based Software as a Medical Device (AI-SaMD), signalling a shift in oversight for assistive AI applications in healthcare. AIGP Health's approval is an early example of what the HSA's approach to responsible AI deployment may mean for medical technology developers in Singapore.
"This milestone gives us the regulatory trust and momentum to move forward on several fronts - including the development of more modular, specialty-specific features, such as rheumatology and chronic care," added Dr Santosa. "It also opens doors to integrate our system more deeply into electronic health records (EHRs), and eventually into diagnostic workflows - all while ensuring that doctors stay in charge."
As part of its continued product development, AIGP Health is working on its own integrated electronic health record solution to better support voice-based commands, clinical ordering, and data integration. The company is also examining future capabilities such as image-based circulatory assessments and multimodal diagnostics.
The current Anzu platform supports a full patient journey, from intake and triage to documentation and follow-up, with multilingual features in English, Malay, Chinese, Tamil, and Bahasa Indonesia. It is designed to offer real-time, evidence-based reasoning and seamless integration with existing clinical systems.
Future developments
The regulatory approval represents a milestone for the business, which has thus far been funded at the pre-seed and seed stage. AIGP Health will soon enter a further seed fundraising round, with its HSA and SOC 2 credentials expected to support its standing among prospective investors.
"Our long-term mission is to help doctors spend more time listening to their patients and less time typing," said Dr Santosa. "This approval brings us one step closer to that future, where AI lightens the load, and healthcare becomes more human again."
